Journal article
Treatment approaches to Mycobacterium abscessus pulmonary disease
Clinics in Chest Medicine, Vol.44(4), pp.785-798
2023
PMID: 37890916
Abstract
Mycobacterium abscessus complex comprises three subspecies. Subspecies abscessus and bolletii usually exhibit inducible macrolide resistance, whereas subspecies massiliense usually does not. Macrolide susceptibility is determined by phenotypic testing after 14 days of incubation. Macrolide susceptibility is the key determinant of treatment outcome for M abscessus pulmonary disease (MAB-PD) and must be protected by adequate companion drugs in treatment regimens. The optimal approach to treatment of MAB-PD is undefined. Current treatment strategies result in poor outcomes, especially for macrolide resistant isolates, and considerable drug toxicity. Multiple novel or repurposed therapeutic candidates are emerging.
Details
- Title
- Treatment approaches to Mycobacterium abscessus pulmonary disease
- Authors
- Michael R. Holt (Corresponding Author) - Royal Brisbane and Women's HospitalTimothy Baird (Author) - University of the Sunshine Coast, Queensland, School of Science, Technology and Engineering
- Publication details
- Clinics in Chest Medicine, Vol.44(4), pp.785-798
- Publisher
- Elsevier Inc.
- Date published
- 2023
- DOI
- 10.1016/j.ccm.2023.06.010
- ISSN
- 1557-8216
- PMID
- 37890916
- Organisation Unit
- University of the Sunshine Coast, Queensland; School of Science, Technology and Engineering
- Language
- English
- Record Identifier
- 99746797802621
- Output Type
- Journal article
Metrics
54 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Web Of Science research areas
- Respiratory System
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: SDGs from InCites